BRAF V600 co-testing is technically feasible in conventional thyroid fine needle aspiration (FNA) cytology smears and can reduce the need for completion thyroidectomy

Cytopathology

Volumn 25, Issue 3, 2014, Pages 155-159

  Poller, D N ^a   Glaysher, S ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

BRAF; Cytology; Diagnosis; Fine needle aspiration; FNA; Papillary thyroid cancer; Thyroid

Indexed keywords

B RAF KINASE; B RAF V600 PROTEIN; UNCLASSIFIED DRUG; BRAF PROTEIN, HUMAN;

ARTICLE; ASPIRATION CYTOLOGY; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; CYTODIAGNOSIS; DNA EXTRACTION; FEASIBILITY STUDY; FINE NEEDLE ASPIRATION BIOPSY; FINE NEEDLE ASPIRATION CYTOLOGY; GENE MUTATION; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID CANCER; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE;

BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; DNA MUTATIONAL ANALYSIS; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY;

EID: 84900797998     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/cyt.12109     Document Type: Article

References (14)

1. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011;135:569-77.
2. Nikiforov YE, Ohori NP, Hodak SP et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-7.
3. Alexander EK, Kennedy GC, Baloch ZW et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012;367:705-15.
4. Rossi ED, Martini M, Capodimonti S et al. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol 2013;168:853-9.
5. Cochand-Priollet B, Dahan H, Laloi-Michelin M et al. Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid:2011;21:1067-73.
6. Kovacs CM, Nose V. Papillary thyroid carcinoma, tall cell variant. In: Diagnostic Endocrine Pathology: Nose V (ed). Salt Lake City: Amirsys Publishing; 2012: 1: pp. 90-92.
7. Cross PA, Chandra A, Giles T et al. Guidance on the reporting of thyroid cytology specimens. http://www.rcpath.org/publications-media/publications/publications.htm#cyto (accessed 4.9.13).
8. Kocjan G, Chandra A, Cross PA et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists' classification system. Am J Clin Pathol 2011;135:852-9.
9. Poller DN, Kandaswamy P. A simplified economic approach to thyroid FNA cytology and surgical intervention in thyroid nodules. J Clin Pathol 2013;66:583-8.
10. Carr R, Ustun B, Chhieng D et al. Radiologic and clinical predictors of malignancy in the follicular lesion of undetermined significance of the thyroid. Endocr Pathol 2013;24:62-8.
11. Sarne DH. A piece of the puzzle: what does BRAF status mean in the management of patients with papillary thyroid carcinoma? J Clin Endocrinol Metab 2012;97:3094-6.
12. Koh J, Choi JR, Han KH et al. Proper indication of BRAF(V600E) mutation testing in fine-needle aspirates of thyroid nodules. PLoS One 2013;8:e64505.
13. Johnson SJ, Hardy S, Roberts C et al. Pilot of BRAF testing in indeterminate (and malignant) thyroid cytology. Cytopathology 2014;25:146-54.
14. Moghaddam PA, Cornejo KM, Khan A. Metastatic carcinoma to the thyroid gland: a single institution 20-year experience and review of the literature. Endocr Pathol 2013;24:116-24.